BRAINSTORM CELL THERAPEUTICS INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $35.5M | $37.8M |
| FY2021 | — | $19.3M | $18.9M |
| FY2022 | — | $-3.0M | $772.0K |
| FY2023 | — | $-4.9M | $1.3M |
| FY2024 | — | $-7.8M | $187.0K |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $35.5M | $37.8M |
| FY2021 | — | $19.3M | $18.9M |
| FY2022 | — | $-3.0M | $772.0K |
| FY2023 | — | $-4.9M | $1.3M |
| FY2024 | — | $-7.8M | $187.0K |